Capital, Manufacturing Market Acceptance Of Therapeutic Cancer Vaccines

Source: Bioprocess Online

Biotechs have been battling through a downturn, and therapeutic cancer vaccine developers have seen no exception. Have RNA-based developers bucked that trend? In this segment of the Bioprocess Online Live event, HDT Bio Chief Scientific Officer Peter Berglund, Ph.D., Codagenix EVP for Oncology Johanna Kaufmann, Ph.D., and Providence Therapeutics President & Chief Technology Officer Robert Georgantas III, Ph.D. discuss the economic headwinds their efforts are facing.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online